Close Menu

More articles about Business, Policy & Funding

The firms said they will focus on increasing Randox’s manufacturing capacity for biochips including those used in SARS-CoV-2 tests.

The New York-based firm will use the funding to develop and clinically validate its personalized, real-time tool for monitoring recurrence and treatment response for various sold cancer types. 

The Swiss company said the higher revenues were driven by an 11 percent year-over-year increase in revenues from its Alba reagent business.

The lawmakers requested the secretary to direct money from the Public Health and Social Services Emergency Fund to support clinical labs.

Promega will seek to expand use of the assay in Europe while it works through regulatory review of the test for companion diagnostic use in the US and Asia.

The company said clinical services revenues and diagnostic testing volumes fell during the quarter due to the negative impact of the COVID-19 pandemic.

The winners will each get a sample set from AACC's Universal Sample Bank, which has blood samples from healthy individuals collected to help medical studies.

Sherlock Bio recently received US Food and Drug Administration Emergency Use Authorization for the kit, which uses CRISPR to detect the virus in patient samples.

The tests are designed to detect and differentiate immunoglobulin M and immunoglobulin G antibodies against SARS-CoV-2 in various blood samples.

The company said it has scaled up production capacity to two million reactions per week and has the potential to scale up to three million reactions per week.

The system detects Zika virus IgM antibodies in human serum, potassium-EDTA plasma, potassium-EDTA venous whole blood, or fingerstick whole blood specimens.

Phosphorus' test is authorized for use with saliva samples collected by healthcare providers or patients at home using DNA Genotek's collection kit.

Hologic received clearance for a change to a probe reagent in the Aptima Combo 2 assay to detect variants of Chlamydia trachomatis that have emerged recently.

ArcherDx has leveraged next-generation sequencing to develop and commercialize more than 325 research-use-only products and a pan-solid tumor diagnostic test.

The test is designed to detect a nucleic acid sequence from the SARS-CoV-2 E gene in various respiratory specimens including nasal swabs.

Private equity firms KKR and Ampersand Capital have reportedly proposed acquiring Oxford Immunotec for around $15 per share in cash.

Finland-based Medix Biochemica said the acquisition of US-based EastCoast Bio broadens its antibody and antigen offering in several diagnostic areas.

The company said it has also received Emergency Use Authorization from the US Food and Drug Administration for its nucleic acid extraction kit.

The company said it is recruiting 200 staff members in science, engineering, and manufacturing to support its role within a national SARS-CoV-2 testing program.

The test measures levels of interleukin 6, which is an indicator for acute inflammation and can be used to identify COVID-19 patients at high risk of intubation.

Pages